The global healthcare sector is currently witnessing a massive influx of capital into advanced diagnostic infrastructure, which is a major catalyst for Immunohistochemistry market growth. As the geriatric population grows, the incidence of age-related cancers and neurodegenerative disorders has increased the reliance on IHC for definitive diagnosis. This has led to the development of next-generation kits that are not only faster but also more cost-effective for medium-scale laboratories.

Technological synergy is also playing a huge role in this expansion. The marriage of immunohistochemistry with in-situ hybridization (ISH) has created a powerful dual-approach for characterizing tumors at both the protein and genetic levels. As pharmaceutical companies increasingly use these methods for clinical trials and drug validation, the market is expanding beyond traditional hospital settings and into specialized contract research organizations (CROs).

FAQ:

• Q: Which end-users are contributing most to market expansion?

• A: Hospitals and diagnostic laboratories remain the largest end-users, while academic and research institutes are the fastest-growing segment due to drug discovery activities.